ANGO Q4 sales $86.6M tops ests $80.4M; Q4 EPS loss (-$0.07) vs. est. loss (-$0.09); guides Fy27 sales outlook $336-$341M as expects Med Tech
ANGO Q4 sales $86.6M tops ests $80.4M; Q4 EPS loss (-$0.07) vs. est. loss (-$0.09); guides Fy27 sales outlook $336-$341M as expects Med Tech net sales growth of 12%–15% and Med Device net sales growth flat; sees gross margin of 54%–55% and adj EBITDA of $13M-$16M for fiscal 2027 (more)
ANGO Q4 sales $86.6M tops ests $80.4M; Q4 EPS loss (-$0.07) vs. est. loss (-$0.09); guides Fy27 sales outlook $336-$341M as expects Med Tech net sales growth of 12%–15% and Med Device net sales growth flat; sees gross margin of 54%–55% and adj EBITDA of $13M-$16M for fiscal 2027 (more)